Schizophrenia Market

Market Overview: 

The 7 major schizophrenia markets reached a value of US$ 9,480.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 15,236.9 Million by 2034, exhibiting a growth rate (CAGR) of 4.4% during 2024-2034.

The schizophrenia market has been comprehensively analyzed in IMARC's new report titled "Schizophrenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schizophrenia is a complex, chronic mental health disorder that often develops in late adolescence or early childhood and is characterized by disruptions in perceptions, thought processes, emotional responsiveness, and social interactions. The early onset of the disease, along with its chronic course, make it a disabling condition for several patients and their families. Schizophrenia patients usually tend to suffer from an array of symptoms, including hallucinations, delusions, disorganized speech or behavior, and impaired cognitive ability. Other symptoms tend to comprise trouble with concentration and movement-related disorders, among others. Schizophrenia patients are usually advised to undergo a psychological evaluation and a complete medical exam. Delusions or hallucinations alone can often be enough to lead to a diagnosis of schizophrenia. Additionally, a urine or blood test can be performed to eliminate alcohol or drug abuse as the cause of the symptoms. Besides this, magnetic resonance imaging (MRI) or computed tomography (CT) can also be used to eradicate the possibility of a brain tumor. An early diagnosis greatly improves a person's chances of recovering from the illness, reducing episodes of psychosis, and coping with psychotic experiences.

The rising incidences of mental illnesses owing to genetic dispositions, specific chemical imbalances in the brain, substance abuse, and psychosocial variables are primarily driving the global schizophrenia market. In addition to this, the growing investments in digital and telecommunication solutions by government bodies and NGOs to promote self-care and mental health awareness are further bolstering the market growth. Moreover, the emerging popularity of injectable-based schizophrenia medications, particularly long-acting injectables owing to their associated benefits, such as effective long-term relapse prevention, increased patient compliance, ease of administration, and fewer adverse effects as compared to oral treatments is also creating a positive outlook for the market. Besides this, several key players are making significant investments in developing second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients. This, in turn, is acting as another growth-inducing factor. Additionally, the escalating utilization of high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs is further augmenting the market growth. They are cost-effective and time-saving alternative for introducing innovative drugs that can be supplied to small-scale clinics and other healthcare providers using this treatment repurposing strategy. Apart from this, the inflating demand for novel drugs with increased efficacy that do not have any adverse reactions on the patient's safety and well-being is expected to drive the schizophrenia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the schizophrenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schizophrenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schizophrenia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the schizophrenia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the schizophrenia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current schizophrenia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the schizophrenia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the schizophrenia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the schizophrenia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the size of the schizophrenia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of schizophrenia?
• What will be the growth rate of patients across the seven major markets?
   

Schizophrenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for schizophrenia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schizophrenia market?